Transcatheter Tricuspid Valve Intervention: What Physicians Should Know About TEER and TTVR
For many years, the tricuspid valve was often referred to as the “forgotten valve” of the heart. While aortic and mitral valve diseases received major attention in structural heart disease, tricuspid regurgitation was frequently diagnosed late and managed mainly with medications, especially in elderly or high-risk patients.
Today, this approach is changing.
With the evolution of structural heart interventions, severe tricuspid regurgitation is now emerging as one of the most important frontiers in advanced cardiology. Newer catheter-based options such as tricuspid TEER and transcatheter tricuspid valve replacement are creating new possibilities for selected patients who may not be ideal candidates for conventional open-heart surgery.
For cardiologists, heart failure specialists, electrophysiologists, internists and valve clinics, the message is clear: severe tricuspid regurgitation should no longer be viewed only as a medical-management condition. Early recognition, careful imaging and timely referral to a structural heart team can significantly change the treatment pathway.
Understanding Tricuspid Regurgitation
The tricuspid valve is located between the right atrium and the right ventricle. It allows blood to move forward through the right side of the heart and prevents backward leakage.
Tricuspid regurgitation, also known as TR, occurs when this valve does not close properly. As a result, blood leaks backward into the right atrium each time the right ventricle contracts.
Mild tricuspid regurgitation may be seen commonly and may not always require intervention. However, when the leakage becomes moderate to severe, it can lead to progressive right-sided heart strain and heart failure symptoms.
Common symptoms may include:
- Breathlessness
- Fatigue
- Swelling of the legs or feet
- Abdominal bloating
- Fluid retention
- Reduced exercise capacity
- Loss of appetite
- Repeated hospital admissions for heart failure
- Liver or kidney congestion in advanced cases
In many patients, these symptoms may be mistaken for ageing, lung disease, kidney problems or worsening general heart failure. This is one reason why tricuspid valve disease may remain under-recognised until it becomes advanced.
Why Severe Tricuspid Regurgitation Matters
Severe tricuspid regurgitation is not just an incidental finding on echocardiography. It can significantly affect quality of life, functional capacity and long-term outcomes.
When the tricuspid valve leaks severely, the right side of the heart has to work harder. Over time, this can lead to:
- Right atrial enlargement
- Right ventricular dilatation
- Worsening right-sided heart failure
- Persistent fluid overload
- Liver congestion
- Kidney dysfunction
- Reduced cardiac efficiency
- Recurrent hospitalisation
Severe TR is often associated with other cardiac conditions such as atrial fibrillation, pulmonary hypertension, left-sided valve disease, pacemaker or ICD leads, and advanced heart failure.
This makes evaluation complex. It also makes heart team decision-making extremely important.
Why Medical Therapy Alone May Not Be Enough
Traditionally, many patients with severe tricuspid regurgitation have been treated with diuretics and heart failure medications. These medicines can help reduce swelling, fluid overload and breathlessness.
However, medical therapy does not directly correct the leaking valve.
For some patients, medicines may improve symptoms temporarily. But when the valve leak is significant, symptoms may return or worsen over time. Repeated adjustments in diuretic doses may also become necessary, especially in patients with kidney dysfunction or advanced heart failure.
This is why physicians should consider early specialist evaluation when a patient has:
- Persistent severe tricuspid regurgitation
- Ongoing symptoms despite medical therapy
- Recurrent leg swelling or fluid retention
- Repeated hospital admission for heart failure
- Worsening right-sided chamber enlargement
- Declining functional capacity
- Pacemaker or ICD lead-related tricuspid valve dysfunction
- Associated atrial fibrillation or pulmonary hypertension
The ideal time for referral is not when the patient has become too sick for intervention. The ideal time is when advanced valve assessment can still help guide a meaningful treatment decision.
The Rise of Transcatheter Tricuspid Valve Therapies
The field of structural heart disease has already transformed the treatment of aortic and mitral valve disease.
TAVR changed the management of aortic stenosis.
MitraClip and other TEER technologies changed the treatment landscape for selected patients with mitral regurgitation.
Now, tricuspid valve disease is entering a similar phase of transformation.
Transcatheter tricuspid valve therapies are designed to treat selected patients using catheter-based techniques, without the need for conventional open-heart surgery. These procedures are typically considered after detailed clinical evaluation, advanced imaging and heart team discussion.
Two major approaches are currently shaping this field:
- Tricuspid TEER — Transcatheter Edge-to-Edge Repair
- TTVR — Transcatheter Tricuspid Valve Replacement
What Is Tricuspid TEER?
Tricuspid TEER stands for transcatheter edge-to-edge repair.
In this procedure, a clip-based device is delivered through a catheter, usually from the vein. The device helps bring parts of the tricuspid valve leaflets closer together so that the valve can close more effectively and reduce the backward leak.
The concept is similar to mitral TEER, but the tricuspid valve has its own anatomical and technical challenges.
Tricuspid TEER may be considered in selected patients with symptomatic severe tricuspid regurgitation, especially when the valve anatomy is suitable for repair.
Important factors include:
- Leaflet anatomy
- Coaptation gap
- Jet location
- Severity of regurgitation
- Right ventricular function
- Pulmonary pressures
- Pacemaker or ICD lead interaction
- Overall frailty and surgical risk
TEER is not suitable for every patient with severe TR. Careful imaging and multidisciplinary assessment are essential.
What Is Transcatheter Tricuspid Valve Replacement?
Transcatheter tricuspid valve replacement, also called TTVR, is a catheter-based procedure where the diseased tricuspid valve is replaced rather than repaired.
This approach may be considered in selected patients with severe symptomatic tricuspid regurgitation when valve replacement is deemed appropriate after heart team evaluation.
TTVR is especially important because some patients may have valve anatomy that is not ideal for repair. For example, the leaflet gap may be too large, the valve may be severely distorted, or repair may not be expected to reduce the leak sufficiently.
In such cases, replacement may offer a different treatment pathway.
However, TTVR requires careful evaluation of:
- Tricuspid annular size
- Right ventricular function
- Right atrial size
- Venous access
- Liver and kidney status
- Pulmonary pressures
- Interaction with existing cardiac device leads
- Long-term anticoagulation considerations
- Overall procedural risk
As with all advanced structural heart procedures, patient selection is the key to achieving good outcomes.
TEER vs TTVR: How Physicians Should Think About Patient Selection
The decision between tricuspid TEER and TTVR is not based only on the severity of regurgitation. It depends on a detailed understanding of the patient’s anatomy, symptoms, comorbidities and procedural suitability.
TEER may be considered when:
- Valve leaflets can be grasped adequately
- The coaptation gap is suitable
- The regurgitation jet is favourable
- Right ventricular function is acceptable
- Repair is expected to provide meaningful reduction in TR
TTVR may be considered when:
- The valve anatomy is less suitable for repair
- The coaptation gap is large
- The regurgitation is torrential or complex
- Replacement is felt to be more effective than repair
- The patient is suitable for valve replacement after heart team review
The most important point is that severe TR should not be evaluated in isolation. It must be assessed in the context of the entire patient — right heart function, rhythm status, lung pressures, kidney function, liver congestion, frailty and quality of life.
The Role of Imaging in Tricuspid Valve Intervention
Imaging is central to the success of transcatheter tricuspid valve therapies.
A standard echocardiogram can identify the presence and severity of tricuspid regurgitation. However, advanced imaging is often required before deciding whether a patient is suitable for TEER or TTVR.
Important imaging tools may include:
- 2D transthoracic echocardiography
- 3D echocardiography
- Transesophageal echocardiography
- CT-based valve and annular assessment
- Right ventricular function evaluation
- Pulmonary pressure estimation
- Assessment of pacemaker or ICD lead interaction
The goal is not only to confirm severe TR. The goal is to understand why the valve is leaking, how advanced the disease is, and whether the patient can benefit from a catheter-based intervention.
Tricuspid Regurgitation and Atrial Fibrillation
Atrial fibrillation is commonly associated with tricuspid regurgitation.
In many patients, long-standing atrial fibrillation causes enlargement of the right atrium and dilation of the tricuspid valve annulus. This can prevent the valve leaflets from closing properly, leading to functional tricuspid regurgitation.
These patients may present with symptoms such as fatigue, breathlessness, swelling and reduced exercise tolerance.
For electrophysiologists and cardiologists, this connection is important. A patient with atrial fibrillation and progressive right-sided chamber enlargement should not be viewed only through the rhythm lens. The tricuspid valve should also be carefully assessed.
This is especially relevant for patients with:
- Long-standing persistent atrial fibrillation
- Right atrial enlargement
- Severe annular dilation
- Heart failure symptoms
- Recurrent fluid retention
- Pacemaker or ICD leads crossing the tricuspid valve
A combined rhythm, valve and heart failure perspective can help identify patients who need advanced evaluation earlier.
Tricuspid Regurgitation and Cardiac Device Leads
Pacemaker and ICD leads can sometimes contribute to tricuspid regurgitation. A lead crossing the tricuspid valve may interfere with leaflet movement, prevent proper valve closure or worsen an already existing leak.
This is an important consideration because many patients with severe TR also have a history of device therapy.
In such patients, evaluation should include:
- Whether the lead is causing or worsening the valve leak
- Whether the lead is restricting leaflet movement
- Whether the TR is primarily lead-related or functional
- Whether transcatheter repair or replacement is technically feasible
- Whether electrophysiology input is needed as part of the heart team discussion
This is one area where collaboration between structural heart specialists and electrophysiologists becomes especially valuable.
When Should Physicians Refer a Patient?
Referral should be considered when a patient has severe tricuspid regurgitation with symptoms or signs of right-sided heart failure.
Important referral triggers include:
- Persistent breathlessness
- Recurrent leg swelling
- Abdominal distension or bloating
- Fatigue out of proportion to other findings
- Repeated need for diuretic escalation
- Recurrent heart failure admissions
- Severe TR on echocardiography
- Progressive right atrial or right ventricular enlargement
- Pacemaker or ICD lead-associated TR
- Atrial fibrillation with significant tricuspid annular dilation
- Declining quality of life despite medical therapy
A practical referral message is:
Do not wait until the patient develops advanced right ventricular failure, severe liver congestion or irreversible end-organ dysfunction. Early valve team evaluation allows more treatment options to be considered.
The Heart Team Approach
Transcatheter tricuspid valve intervention requires a multidisciplinary heart team approach.
The heart team may include:
- Interventional cardiologists
- Structural heart specialists
- Heart failure specialists
- Electrophysiologists
- Cardiac imaging experts
- Cardiothoracic surgeons
- Anaesthesia and intensive care specialists
- Valve clinic coordinators
Each patient must be assessed individually. The decision should be based on symptoms, anatomy, imaging, procedural risk, comorbidities and expected benefit.
A successful tricuspid valve programme is not only about performing a procedure. It is about identifying the right patient at the right stage of disease.
Why This Is the Next Frontier in Structural Heart Disease
Structural heart disease has moved rapidly over the last two decades.
First, transcatheter valve therapy transformed the treatment of aortic stenosis. Then, catheter-based mitral repair expanded options for patients with mitral regurgitation. Now, tricuspid valve disease is receiving the attention it deserves.
This is clinically important because severe tricuspid regurgitation is common, often under-treated and frequently associated with significant symptoms.
For selected patients, transcatheter therapies may offer a less invasive treatment pathway. For physicians, this means that severe TR should be recognised earlier, investigated more carefully and referred more proactively.
The tricuspid valve is no longer the forgotten valve.
It is now one of the most important areas in the future of structural heart intervention.
Dr. AB Gopalamurugan’s Perspective
Dr. A.B. Gopalamurugan is a Senior Interventional Cardiologist and Electrophysiologist known for his work in complex cardiac interventions, electrophysiology, transcatheter valve therapies and endovascular interventions.
With extensive training in London and advanced expertise in structural heart disease, Dr. Gopalamurugan brings a comprehensive approach to patients with complex valve and rhythm disorders. His work in transcatheter valve therapy reflects the growing need for advanced, minimally invasive solutions for patients who may not be suitable for conventional surgery.
As tricuspid valve therapies continue to evolve, the focus must remain on early diagnosis, detailed imaging, careful patient selection and multidisciplinary decision-making.
Conclusion
Severe tricuspid regurgitation should no longer be seen as a condition with limited treatment possibilities. While medical therapy remains important for symptom control, newer transcatheter options such as tricuspid TEER and transcatheter tricuspid valve replacement are changing the treatment landscape for selected patients.
For physicians, the key message is simple:
Identify severe TR early. Assess the right heart carefully. Refer suitable patients before the disease becomes too advanced.
The future of structural heart disease is not limited to the aortic and mitral valves. The tricuspid valve is now a major frontier — and timely specialist evaluation can make a meaningful difference for patients.
FAQs
What is tricuspid regurgitation?
Tricuspid regurgitation is a condition where the tricuspid valve does not close properly, allowing blood to leak backward into the right atrium.
What are the symptoms of severe tricuspid regurgitation?
Symptoms may include breathlessness, fatigue, leg swelling, abdominal bloating, fluid retention and repeated heart failure admissions.
Can tricuspid regurgitation be treated without open-heart surgery?
In selected patients, catheter-based treatments such as tricuspid TEER or transcatheter tricuspid valve replacement may be considered.
What is tricuspid TEER?
Tricuspid TEER is a minimally invasive catheter-based repair technique that helps reduce valve leakage by improving leaflet closure.
What is TTVR?
TTVR stands for transcatheter tricuspid valve replacement. It is a catheter-based approach where the diseased tricuspid valve is replaced rather than repaired.
Who should be referred for tricuspid valve evaluation?
Patients with severe TR, persistent symptoms, recurrent swelling, heart failure admissions, right heart enlargement or poor response to medical therapy should be considered for advanced valve evaluation.
Is every patient with severe TR suitable for TEER or TTVR?
No. Suitability depends on valve anatomy, right heart function, pulmonary pressures, comorbidities, imaging findings and heart team assessment.
tricuspid TEER, tricuspid valve intervention, transcatheter tricuspid valve replacement, TTVR, TriClip, EVOQUE valve, tricuspid regurgitation treatment, severe TR treatment, structural heart disease, right-sided heart failure, valve disease treatment
